Abstract

Many translational cancer research studies are based on the study of human cancer tissues. This research requires access to samples of human cancers and corresponding normal tissues and also requires expertise of qualified pathologists to assist in the appropriate use of tissues and interpretation of results. The purpose of this core is to provide a centralized resource for collecting and processing samples of solid tumors and hematologic malignancies based on the needs of Cancer Center investigators. The procurement of solid tumor tissues by the Core frequently involves selection of appropriate paraffin tissue blocks as well as collection of fresh-frozen tissue samples. The Core also provides a centralized laboratory resource for conducting immunohistochemistry, and in response to increased requests for immunochemistry on breast cancer samples, is developing breast cancer tissue arrays. Finally, the Core provides consultative services for the assessment of tissue samples and the development and interpretation of immunohistochemistry assays.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-39
Application #
6481450
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1978-01-01
Project End
2006-04-30
Budget Start
Budget End
Support Year
39
Fiscal Year
2001
Total Cost
Indirect Cost

  Institution

Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218

  Publications

Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Isaacsson Velho, Pedro; Antonarakis, Emmanuel S (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 11:475-486
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Cuviello, Andrea; Goyal, Anshit; Zick, Aviad et al. (2018) Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic BRAF. JCO Precis Oncol 2018:
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663

Showing the most recent 10 out of 2393 publications